BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14677621)

  • 1. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():9-15. PubMed ID: 14677620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
    van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women.
    Oosterbaan HP
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():3-8. PubMed ID: 14677619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
    Halbe HW; de Melo NR; Bahamondes L; Petracco A; Lemgruber M; de Andrade RP; da Cunha DC; Guazelli CA; Baracat EC
    Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
    Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
    Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
    Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
    Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
    Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
    Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.